Comparative Pharmacology
Head-to-head clinical analysis: METROCREAM versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROCREAM versus METROLOTION.
METROCREAM vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
Topical, apply a thin film to affected area once or twice daily.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)